Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
Objective. To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in the Russian healthcare system. Materials and method...
| Main Authors: | , , , , |
|---|---|
| פורמט: | Article |
| שפה: | Russian |
| יצא לאור: |
Izdatelstvo OKI
2020-05-01
|
| סדרה: | Качественная клиническая практика |
| נושאים: | |
| גישה מקוונת: | https://www.clinvest.ru/jour/article/view/485 |